Xintela’s operations are based on a patented technology platform, XINMARK™, from which the company makes use of specific markers to develop new treatments and diagnostics in regenerative medicine and cancer. The company is listed on Nasdaq First North Stockholm.
Xintela
Xintela is a biomedical company working in the fields of regenerative medicine and cancer, with particular focus on two areas in which there is great need for new and better treatments: cartilage damage and brain tumours.
